Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Recombinant Therapeutic Antibodies and Proteins Market, by Drug Class (Plasma Protein, Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 91.2 billion in 2017 and is expected to exhibit a CAGR of 12.2% over the forecast period (2018-2026).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1981
Recombinant therapeutic antibodies and proteins market is expected to witness significant growth over the forecast period, attributed to rising advancements in the development of recombinant therapeutic drugs.
Increasing focus on recombinant therapeutics for drug development is expected to drive growth of the recombinant therapeutic antibodies and proteins market over the forecast period.
The increasing demand for recombinant therapeutic antibodies and proteins to improve the existing expression systems or developing novel approaches, in order to cater to growing demand for new therapeutics is expected to drive the market growth over the forecast period.
Moreover, pharmaceutical recombinant protein is increasingly adopted for the treatment of diseases such as cancer, diabetes, anemia, and hepatitis. Medicinal and industrial usage of recombinant protein in drug manufacturing is rising, coupled with increasing demand for various protein expression systems and other related high-tech systems, which are expected to drive the market growth. Furthermore, recombinant therapeutic antibodies and proteins market is expected to exhibit high growth, attributed to increasing adoption of protein-engineering technologies and government support for its development. For instance, in 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed to provide the FDA with the capability to establish breakthrough therapy designation (BTD), a new program within the Expedited Programs for Serious Conditions. It was designed to make availability of the drugs used to treat serious illness that have shown to exhibit clinical evidence of significant improvement in comparison to existing treatments.
Moreover, existing therapies can be optimized to achieve better drug targeting and enhancing functionality and potency by modifying or introducing new drug activities, leading to customization of existing proteins or development of novel therapeutics for specific clinical applications. The companies are focusing on engineering strategies and rational design to modify drug activity for development of novel therapeutics related to specific clinical requirements. For instance, in 2015, alirocumab injection (Praluent, Regeneron/Sanofi), the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors received the FDA approval.
Browse 22 Market Data Tables and 27 Figures spread through 160 Pages and in-depth TOC on “Recombinant Therapeutic Antibodies and Proteins Market, by Drug Class (Plasma Protein, Growth factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights prevalent in the recombinant therapeutic antibodies and proteins market, click the link below: https://bit.ly/3iIdddZ
Key Takeaways of the Recombinant Therapeutic Antibodies and Proteins Market:
- The global recombinant therapeutic antibodies and proteins market size is expected to exhibit a CAGR of 12.2% over the forecast period, attributed to increasing focus of key players on recombinant therapeutics for drug development
- Among drug class, monoclonal antibodies segment accounted for a significant market share in the recombinant therapeutic antibodies and proteins market, in 2017, owing to increasing applications of mAbs in therapeutics
- Among application, hematology segment accounted for a significant market share in the recombinant therapeutic antibodies and proteins market, in 2017, attributed to increasing number of regulatory approved products available in this category.
- Among region, North America is expected to hold a dominant position in the global recombinant therapeutic antibodies and proteins market, attributed to increasing R&D expenditure and increasing number of regulatory product approvals.
- Major players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1981
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027